N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide
• 化学式: C₃₀H₃₂N₆O₂S
• 分子量: 540.7
• InChiKey: FCCKVIBNRYEKBV-QJOMJCCJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• US20140275033A1
  申请人：——

  公开号：US20140275033A1

  公开（公告）日：2014-09-18
• US20140275076A1
  申请人：——

  公开号：US20140275076A1

  公开（公告）日：2014-09-18
• 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER
  申请人：Boston Biomedical, Inc.

  公开号：US20190241569A1

  公开（公告）日：2019-08-08

  The invention provides novel inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, and methods of making such compounds and compositions.
• HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE
  申请人：Boston Biomedical, Inc.

  公开号：US20190241550A1

  公开（公告）日：2019-08-08

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R 1 is optionally substituted heteroaryl etc.; R 2 is hydrogen etc.; R 3 and R 4 are each independently hydrogen etc., R 5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R 9a is optionally substituted aryl etc., R 9b and R 9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R 6 is hydrogen etc.; and R 7 is hydrogen etc.
• US9187454B2
  申请人：——

  公开号：US9187454B2

  公开（公告）日：2015-11-17